Results 71 to 80 of about 3,619 (166)

Mpox in endemic regions in Nigeria: awareness, knowledge, and willingness to accept the mpox vaccine

Pan African Medical Journal
Nigeria ranks second in Africa for the highest number of mpox cases. This study aimed to evaluate the knowledge and awareness of mpox among Nigerians living in endemic regions and their willingness to accept the mpox vaccine when available.we conducted a cross-sectional study using a multi-stage sampling technique.
Olufadewa, Isaac Iyinoluwa, Adesina, Miracle Ayomikun, Oladele, Ruth Ifeoluwa, Olufadewa, Toluwase Ayobola, Okpokoro, Evaezi, Daodu, Oluwafemi Babatunde, Ige, Fehintola, Adebajo, Sylvia, Igumbor, Ehimario Uche, Oladoye, Moyinoluwa Joshua, Shaibu, Joseph Ojonugwa, Ogoina, Dimie, Audu, Rosemary Ajuma   +12 more
openaire   +3 more sources

Developing accessible and affordable tests to support mpox immunosurveillance and vaccine studies

Emerging Microbes and Infections
Mpox is an ongoing threat to international health security requiring ongoing research. Antibody tests are needed for surveillance studies to understand clinical and sub-clinical transmission risks and respond to outbreaks.
Sian E. Faustini, Scott Jones, Christopher A. Green, Ashley D. Otter, Alex G. Richter, Jennifer L. J. Heaney   +5 more
doaj   +1 more source

Pro-inflammatory cytokine profiles and neutralizing antibodies in JYNNEOS-vaccinated and mpox-diagnosed individuals

npj Vaccines
Mpox is a significant health concern as an infectious disease. Therefore, understanding the immune response triggered in individuals vaccinated with JYNNEOS and those diagnosed with mpox requires further investigation.
Mariella Sousa Coêlho Maciel, Adriana de Souza Andrade, Ana Luiza Neri de Oliveira, Nidia Esther Colquehuance Arias, Silvia Hess de Carvalho, Marcelo Antonio Pascoal Xavier, Erna Geessien Kroon, Marco Antônio Campos   +7 more
doaj   +1 more source

A theory-based assessment of mpox: Findings from a nationally representative survey of U.S. adults.

PLoS ONE
The purpose of this research was to examine individual differences related to fear of, perceived susceptibility to, and perceived severity of mpox as well as mpox knowledge, fear, perceived susceptibility, and perceived severity as predictors of vaccine ...
Margaret L Walsh-Buhi, Rebecca F Houghton, Danny Valdez, Eric R Walsh-Buhi   +3 more
doaj   +1 more source

A cross-sectional study of Mpox Knowledge, Attitudes toward Mpox Vaccination and Mpox Vaccine Hesitancy Among Teachers in Kenya

Abstract Background: Sixteen African countries, including Kenya, reported mpox cases in July and August, prompting the Africa Centers for Disease Control to declare the outbreak a Public Health Emergency of Continental Security on 13th August 2024.
Patrick M.Mutua, Micahel M. Gicheru, Joshua Mutiso, Erick Serem   +3 more
openaire   +1 more source

The Current State and Progress of Mpox Vaccine Research

China CDC Weekly
On July 23, 2022, the World Health Organization (WHO) declared the monkeypox (mpox) outbreak a "Public Health Emergency of International Concern." Since 2022, outbreaks of mpox in many countries around the world have primarily resulted in fatalities among immunocompromised individuals, such as untreated HIV/AIDS patients.
Wang, Xinlong, Gu, Zhixia, Sheng, Shugui, Song, Rui, Jin, Ronghua   +4 more
openaire   +2 more sources

Mpox Epidemiology and Vaccine Effectiveness, England, 2023

Emerging Infectious Diseases
Reported mpox cases in England continued at a low but steady frequency during 2023. Of 137 cases reported in 2023, approximately half were acquired overseas and half were in vaccinated persons. Estimated effectiveness of 2-dose vaccine was 80%, and no vaccinated mpox patient was hospitalized.
Hannah Charles, Katie Thorley, Charlie Turner, Kirsty F. Bennet, Nick Andrews, Marta Bertran, Sema Mandal, Gayatri Amirthalingam, Mary E. Ramsay, Hamish Mohammed, Katy Sinka   +10 more
openaire   +3 more sources

Differences in Mpox and Vaccinia Immunity Induced by Non-Replicating and Replicating Vaccinia-Based Vaccines

Vaccines
Background: The recent global outbreak with clade IIb and the concurrent emergence of clade I mpox virus in Africa show that mpox is a challenging problem. MVA-BN induces low-level mpox-neutralizing antibody responses that wane rapidly.
Getahun Abate, Krystal Meza, Yinyi Yu, Chase Colbert, Anna Jaunarajs, Azra Blazevic, Daniel F. Hoft, Sharon E. Frey   +7 more
doaj   +1 more source

Vaccine effectiveness of 3rd generation mpox vaccines against mpox and disease severity: A systematic review and meta-analysis

Vaccine
Before the global mpox outbreak which began in 2022, the real-world vaccine effectiveness (VE) of mpox vaccines was unknown. We quantified the VE in the global population of 3rd generation or later mpox vaccines (MVA-BN, LC16m8, OrthopoxVac) compared with unvaccinated or other vaccinated states for infection, hospitalization and death.
Lauren Pischel, Brett A. Martini, Natalle Yu, David Cacesse, Mahder Tracy, Kolambi Kharbanda, Noureen Ahmed, Kavin M. Patel, Alyssa A. Grimshaw, Amyn A. Malik, George Goshua, Saad B. Omer   +11 more
openaire   +2 more sources

Determinants of Mpox vaccine uptake and hesitancy among healthcare workers in Port Harcourt, Nigeria

BMC Infectious Diseases
Background Mpox is a re-emerging zoonotic disease of global public health concern. Healthcare workers (HCWs) face elevated occupational risk and influence community vaccination behaviour, yet evidence on mpox vaccine uptake and hesitancy among Nigerian ...
Moore Ikechi Mike-Ogburia, Chiziyara Orluibna Obunwo, Elizabeth Efeelobari Letam, Ayebaemi Wilfred Dambo, Samuel Chima Agumagu, Tamunosaki Fubara-Manuel, Charles Henry Esukpa   +6 more
doaj   +1 more source